When formulated with smallpox, HIV-1, influenza, or hepatitis B antigens and delivered intranasally, these adjuvants mediated the production of not only robust virus neutralizing antibodies, but also IFN-γ and TNF-α, as well as elevated IgG2a and mucosal IgA levels. This evidence concerns the gene TNF and influenza.